Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.

Cayssials E, Guilhot F.

Haematologica. 2019 Jun;104(6):1096-1098. doi: 10.3324/haematol.2019.217034. No abstract available.

2.

Response to pneumococcal vaccination in multiple myeloma.

Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, Cayssials E, Bories C, Herbaux C, Systchenko T, Faucompré JL, Machet A, Sabirou F, Levy A, Bobin A, Richez V, Moya N, Gruchet C, Desmier D, van de Wyngaert Z, Carpentier B, Manier S, Facon T, Harding S, Leleu X.

Cancer Med. 2019 May 30. doi: 10.1002/cam4.2253. [Epub ahead of print]

3.

Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.

Cayssials E, Jacomet F, Piccirilli N, Lefèvre L, Roy L, Guilhot F, Chomel JC, Leleu X, Gombert JM, Herbelin A, Barbarin A.

Br J Haematol. 2019 Jul;186(1):54-59. doi: 10.1111/bjh.15858. Epub 2019 Mar 12.

PMID:
30864168
4.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
5.

Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).

Desterke C, Voldoire M, Bonnet ML, Sorel N, Pagliaro S, Rahban H, Bennaceur-Griscelli A, Cayssials E, Chomel JC, Turhan AG.

Exp Hematol. 2018 Aug;64:71-83.e8. doi: 10.1016/j.exphem.2018.04.007. Epub 2018 May 5.

PMID:
29733872
6.

Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort.

Puyade M, Cayssials E, Pierre F, Pourrat O.

Obstet Med. 2017 Dec;10(4):165-169. doi: 10.1177/1753495X17708896. Epub 2017 Aug 4.

7.

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.

Cayssials E, Tartarin F, Guilhot J, Sorel N, Chomel JC, Leleu X, Guilhot F.

Leuk Lymphoma. 2018 Mar;59(3):766-769. doi: 10.1080/10428194.2017.1357178. Epub 2017 Aug 9. No abstract available.

PMID:
28792265
8.

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.

PMID:
28772207
9.

Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.

Cayssials E, Guilhot F.

BioDrugs. 2017 Jun;31(3):143-149. doi: 10.1007/s40259-017-0225-6. Review.

PMID:
28501913
10.

Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases.

Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert JM.

Front Immunol. 2017 Mar 27;8:316. doi: 10.3389/fimmu.2017.00316. eCollection 2017.

11.

Treatment and molecular monitoring update in chronic myeloid leukemia management.

Sorel N, Cayssials É, Brizard F, Chomel JC.

Ann Biol Clin (Paris). 2017 Apr 1;75(2):129-145. doi: 10.1684/abc.2017.1233. Review.

PMID:
28377326
12.

The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia.

Jacomet F, Cayssials E, Barbarin A, Desmier D, Basbous S, Lefèvre L, Levescot A, Robin A, Piccirilli N, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM.

Front Immunol. 2017 Jan 16;7:688. doi: 10.3389/fimmu.2016.00688. eCollection 2016.

13.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

14.

Beyond tyrosine kinase inhibitors: Combinations and other agents.

Cayssials E, Guilhot F.

Best Pract Res Clin Haematol. 2016 Sep;29(3):271-283. doi: 10.1016/j.beha.2016.10.017. Epub 2016 Oct 20. Review.

PMID:
27839568
15.

Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma.

Cassou-Mounat T, Delwail V, Cayssials E, Terroir M, Puyade M.

Leuk Lymphoma. 2016;57(3):724-5. doi: 10.3109/10428194.2015.1070152. Epub 2015 Aug 13. No abstract available.

PMID:
26148876
16.

Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples.

Jacomet F, Cayssials E, Basbous S, Levescot A, Piccirilli N, Desmier D, Robin A, Barra A, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM.

Eur J Immunol. 2015 Jul;45(7):1926-33. doi: 10.1002/eji.201545539. Epub 2015 May 20.

Supplemental Content

Loading ...
Support Center